Buprenorphine Treatment Centers in Hawaii

buprenorphine is approved for opioid use disorder involving any opioid — heroin, fentanyl, prescription oxycodone, hydrocodone, or morphine. Hawaii clinicians treat patients whose OUD started with a pain prescription just as readily as those using illicit opioids.

Many Hawaii community behavioral-health agencies and federally qualified health centers offer sliding-scale fees based on household income. Sliding-scale fees commonly bring a weekly methadone visit down to $5–$25. Ask buprenorphine providers in your area about discounted rates when you call.

Yes. Med-QUEST covers FDA-approved medications for opioid use disorder, including buprenorphine, plus the associated counseling, drug testing, and clinic visits. Specific formulary details (preferred agents, long-acting injectables) vary by plan — check with your Med-QUEST managed-care organization.

Yes. Blue Cross Blue Shield plans in Hawaii cover all three FDA-approved MAT medications. BCBS typically requires the provider to be in-network; most major buprenorphine providers in Kaneohe and across Hawaii accept BCBS.

Clinics maintain a confidential medical record covering diagnosis, treatment plan, drug screens, counseling notes, and dose history. Records are protected by 42 CFR Part 2 — stricter than HIPAA — and cannot be released without your written consent or a specific court order.

Yes. Cross-titration between methadone and buprenorphine is a routine clinical maneuver in Hawaii. Transfer from methadone to buprenorphine is technically more challenging (risk of precipitated withdrawal) and usually requires a structured micro-induction protocol supervised by an experienced clinician.

Bring a photo ID, insurance or Med-QUEST card (if applicable), and a list of current medications. Proof of address and pharmacy information speed up buprenorphine prescribing. Intake staff will walk you through paperwork at your first visit.

Hawaii programs generally recommend arranging a ride for the first induction visit, since initial drowsiness is common. After the first 1–2 weeks at a stable dose, patients typically resume driving and most daily activities without restriction.

Yes. Decades of research support the long-term safety of methadone, buprenorphine, and naltrexone when appropriately prescribed. Long-term MAT is associated with lower mortality, reduced infectious disease, and improved quality of life. Hawaii patients frequently remain on MAT for years without medical complications.

Methadone doses often need increase in the third trimester due to increased metabolism; split dosing may be needed. Buprenorphine sometimes requires modest increases. Your Hawaii MAT team and OB will monitor closely and adjust dosing based on cravings and withdrawal.

Yes. Med-QUEST covers individual therapy, group sessions, and care coordination at Hawaii MAT clinics without separate deductibles in most plans. Peer-recovery support services are also covered in Hawaii.

No. Your Hawaii clinic cannot share any information with family members without a signed release specifying who, what information, and for how long. Patients under 18 may have parental involvement requirements — rules vary.